Floatz logo

sct200

Triple Negative Breast Neoplasms

Sinocelltech Ltd.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

448 Active assets in the Triple Negative Breast Neoplasms cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

sct200 is also rated in:

colorectal cancerDormant
CCC
Indicative ·
52 / 100
View asset →
non-small cell squamous lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
esophageal squamous cell carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →